Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02709226 : Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
PhasePhase 1
AgesMin: 18 Years Max: 99 Years

1. Histological diagnosis

Previous histologic diagnosis of glioblastoma, transformation to glioblastoma or
gliosarcoma established by biopsy or resection prior to enrollment as evident on
NIH or outside pathology.

2. Patients must be age greater than or equal to 18.

3. Patients should have a KPS greater than or equal to 70%

4. Prior standard radiation therapy to a dose ranging from 50 to 60 Gy at 1.8 to 2
Gy per fraction.

5. Patients must be more than or equal to 14 days from previous cytotoxic treatment.

6. Concurrent therapy

The concurrent use of bevacizumab is allowed if previously initiated for tumor
progression or symptomatic management. Prior temozolomide or other cytotoxic
chemotherapy is allowed.

7. Ability of subject or Legally Authorized Representative (LAR) to understand and
the willingness to sign a written informed consent document.

8. Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry
and for the duration of study participation. Should a woman become pregnant or
suspect she is pregnant while she or her partner is participating in this study,
she should inform her treating physician immediately.


1. Prior therapy < than 2 weeks since surgical re-resection or biopsy

2. Pregnant or breast feeding females are excluded due to potential mutagenic effects on
the developing fetus or newborn

3. Preexisting grade 3 or 4 nervous system disorder as per CTCAE Version 4.03

4. Clinically significant unrelated systemic illness (including but not limited to active
life threatening infection, cardiac or neurologic events, current hospital admission
for a coexisting comorbid illness), which would make it impossible for the patient to
tolerate re-irradiation or systemic chemotherapy or likely to interfere with the

5. Patients exhibiting baseline grade 3 or 4 by CTCAE criteria are excluded due to
difficulty in assigning these to the study intervention as treatment related DLT.

6. Patients with preexisting known or suspected radiation sensitivity syndromes will be
excluded due to potential confounding effect on outcome.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557